Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Clin Med (Lond) ; 24(3): 100202, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38642612

RESUMO

BACKGROUND: Recurrent FUO (fever of unknown origin) is a rare subtype of FUO for which diagnostic procedures are ill-defined and outcome data are lacking. METHODS: We performed a retrospective multicentre study of patients with recurrent FUO between 1995 and 2018. By multivariate analysis, we identified epidemiological, clinical and prognostic variables independently associated with final diagnosis and mortality. RESULTS: Of 170 patients, 74 (44%) had a final diagnosis. Being ≥ 65 years of age (OR = 5.2; p < 0.001), contributory history (OR = 10.4; p < 0.001), and abnormal clinical examination (OR = 4.0; p = 0.015) independently increased the likelihood of reaching a diagnosis, whereas lymph node and/or spleen enlargement decreased it (OR = 0.2; p = 0.004). The overall prognosis was good; 58% of patients recovered (70% of those with a diagnosis). Twelve (7%) patients died; patients without a diagnosis had a fatality rate of 2%. Being ≥ 65 years of age (OR = 41.3; p < 0.001) and presence of skin signs (OR = 9.5; p = 0.005) significantly increased the risk of death. CONCLUSION: This study extends the known yield of recurrent FUO and highlights the importance of repeated complete clinical examinations to discover potential diagnostic clues during follow-up. Moreover, their overall prognosis is excellent.


Assuntos
Febre de Causa Desconhecida , Humanos , Estudos Retrospectivos , Masculino , Feminino , Pessoa de Meia-Idade , Febre de Causa Desconhecida/etiologia , Febre de Causa Desconhecida/epidemiologia , Idoso , Adulto , França/epidemiologia , Recidiva , Prognóstico , Idoso de 80 Anos ou mais , Adolescente , Adulto Jovem
2.
Rev Med Interne ; 39(6): 427-430, 2018 Jun.
Artigo em Francês | MEDLINE | ID: mdl-29526328

RESUMO

INTRODUCTION: Upper digestive symptoms may be present in up to 50% of patients with primary Sjögren syndrome (pSS). We report a retrospective cohort of gastroparesis in a population of pSS presenting unexplained dyspepsia. Delayed gastric emptying was defined by a gastric emptying time above 113min or by a retention percentage at 4h more than 10% on scintigraphy. RESULTS: Eleven patients with primary Sjögren syndrome and gastroparesis were included in a retrospective study. Every patients were women of age 48±18y. The average time of gastric emptying was 725,18±704,45min. 64% of patients had abdominal pain or gastric heaviness. A central or peripheral neurologic involvement was described in respectively 9 and 27% of cases. The diagnostic delay of gastroparesis was higher than 24 months. CONCLUSION: In primary Sjögren syndrome, gastroparesis should be suspected in case of unexplained dyspepsia, and a scintigraphy performed to prove the diagnosis. A neurologic involvement could explain gastroparesis, but prospective studies are needed for a better understanding of this disorder.


Assuntos
Dispepsia/etiologia , Gastroparesia/complicações , Síndrome de Sjogren/complicações , Adulto , Idoso , Diagnóstico Tardio , Dispepsia/diagnóstico , Dispepsia/epidemiologia , Dispepsia/terapia , Feminino , Gastroparesia/diagnóstico , Gastroparesia/epidemiologia , Gastroparesia/terapia , Humanos , Pessoa de Meia-Idade , Cintilografia , Estudos Retrospectivos , Síndrome de Sjogren/epidemiologia , Síndrome de Sjogren/terapia
3.
Rev Med Interne ; 38(7): 482-487, 2017 Jul.
Artigo em Francês | MEDLINE | ID: mdl-27889325

RESUMO

INTRODUCTION: Erdheim-Chester disease and langerhans cell histiocytosis are two rare diseases separate on clinical, radiological and histological aspects. However, several cases involving both entities have been described. OBSERVATION: A 70-year-old man had a central diabetes insipidus, xanthelasmas, retroperitoneal fibrosis and osteosclerosis of the legs suggestive of Erdheim-Chester disease. Bone biopsy showed langerhans cell histiocytosis CD1a positive with the presence of BRAF V600E mutation. The patient was treated with vemurafenib with a good clinical course. CONCLUSION: The literature review finds forty observations linking the two diseases that may suggest a pathophysiological link, especially with the hematopoietic myeloid stem cell CD34+. The term inflammatory myeloid neoplasm was advanced.


Assuntos
Doença de Erdheim-Chester/complicações , Histiocitose de Células de Langerhans/complicações , Idoso , Progressão da Doença , Doença de Erdheim-Chester/patologia , Histiocitose de Células de Langerhans/patologia , Humanos , Masculino , Doenças Raras
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA